Paul Schwarzenberger

Title: Paul Schwarzenberger: Innovator in Gene Therapy

Introduction

Paul Schwarzenberger is a notable inventor based in New Orleans, LA (US). He has made significant contributions to the field of gene therapy, particularly in the treatment of leukemia. His innovative approach aims to selectively target and eliminate leukemia cells while preserving healthy hematopoietic stem cells.

Latest Patents

Schwarzenberger holds a patent for a groundbreaking gene therapy system designed to purge leukemia cells from hematopoietic stem cells. This system utilizes a high-efficiency gene transfer vector that carries a eukaryotic expression construct encoding a toxin gene. The toxin gene is specifically expressed in leukemia cells, leaving stem cells unaffected. This differential expression is achieved through the use of appropriate promoters, such as the RSV promoter or the SV40 promoter. The treatment has shown promise not only for leukemia patients but also for those undergoing autologous bone marrow transplants for other cancers, such as breast or lymphoma cancers. He has 1 patent to his name.

Career Highlights

Schwarzenberger is affiliated with Louisiana State University and Agricultural & Mechanical College, where he continues to advance his research in gene therapy. His work has the potential to revolutionize treatment options for cancer patients, providing a more targeted and effective approach to therapy.

Collaborations

One of his notable collaborators is Jay Kennedy Kolls, with whom he has worked on various research initiatives aimed at improving cancer treatment methodologies.

Conclusion

Paul Schwarzenberger's innovative contributions to gene therapy exemplify the potential of targeted treatments in oncology. His work not only addresses the challenges of leukemia but also opens new avenues for treating other cancers.